Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol — United States, May–August 2022
Author:
- Kevin O’laughlinKOKevin O’laughlin
Open Access
- 16 September 2022
- journal article
- research article
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 71 (37) , 1190-1195
Abstract
This report describes the safety of the use of Tecovirimat to treat monkeypox.Keywords
This publication has 10 references indexed in Scilit:
- Orthopoxvirus Testing Challenges for Persons in Populations at Low Risk or Without Known Epidemiologic Link to Monkeypox — United States, 2022MMWR. Morbidity and Mortality Weekly Report, 2022
- Compassionate Use of Tecovirimat for the Treatment of Monkeypox InfectionJAMA, 2022
- Epidemiologic and Clinical Characteristics of Monkeypox Cases — United States, May 17–July 22, 2022MMWR. Morbidity and Mortality Weekly Report, 2022
- Antivirals With Activity Against Mpox: A Clinically Oriented ReviewClinical Infectious Diseases, 2022
- Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysisThe Lancet Infectious Diseases, 2022
- Clinical features and management of human monkeypox: a retrospective observational study in the UKThe Lancet Infectious Diseases, 2022
- Clinical Course and Outcome of Human Monkeypox in NigeriaClinical Infectious Diseases, 2020
- The development and approval of tecoviromat (TPOXX®), the first antiviral against smallpoxAntiviral Research, 2019
- Oral Tecovirimat for the Treatment of SmallpoxNew England Journal of Medicine, 2018
- Effective Antiviral Treatment of Systemic Orthopoxvirus Disease: ST-246 Treatment of Prairie Dogs Infected with Monkeypox VirusJournal of Virology, 2011